We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

WATERS CORPORATION

Waters Corp. designs, manufactures, sells and services ultra performance liquid chromatography (UPLC), high performan... read more Featured Products: More products

Download Mobile App




Fecal Fat Points to Early Presence of Colorectal Cancer

By LabMedica International staff writers
Posted on 11 Nov 2016
Print article
Image: The Synapt G2 travelling wave ion mobility mass spectrometer (Photo courtesy of Waters).
Image: The Synapt G2 travelling wave ion mobility mass spectrometer (Photo courtesy of Waters).
Colorectal cancer (CRC) remains a leading cause of cancer mortality worldwide, and therefore more accessible screening tests are urgently needed to identify early-stage lesions. Colonoscopy, for example, is a known lifesaver but is costly and unappealing to many people who might otherwise undergo testing.

The use of ultrasensitive, high-speed technology has identified a suite of molecules in the feces of mice that signifies the presence of precancerous polyps and this "metabolic fingerprint" matches changes in both mouse and human colon tumor tissues and suggests a potential new diagnostic tool for early detection of colorectal cancer in a clinical setting.

Scientists at the Washington State University (Pullman, WA, USA) and their colleagues hypothesized that highly sensitive, metabolic profile analysis of stool samples will identify metabolites associated with early-stage lesions and could serve as a noninvasive screening test. They first identified metabolic products from normal colon tissue in both humans and mice and then compared this normal profile to that found in cancerous colon tissues from humans and research mice with polyps in their colons that mimic those in humans.

The investigators applied travelling wave ion mobility mass spectrometry (TWIMMS) coupled with ultra-performance liquid chromatography (UPLC) to investigate metabolic aberrations in stool samples in a transgenic model of pre-malignant polyposis aberrantly expressing the gene encoding the high mobility group A (Hmga1) chromatin remodeling protein. Metabolic extract samples were analyzed by use of a Synapt G2-TWIMMS instrument and chromatographic pre-separation was achieved by use of an ACQUITY UPLC instrument and eluent was introduced to the TWIMMS system via electrospray ionization (ESI) (Waters Corporation, Manchester, UK).

The scientists found that the fecal metabolome of Hmga1 mice is distinct from that of control mice and includes metabolites previously identified in human CRC. Significant alterations were observed in fatty acid metabolites and metabolites associated with bile acids (hypoxanthine xanthine, taurine) in Hmga1 mice compared to controls. Surprisingly, a marked increase in the levels of distinctive short, arginine-enriched, tetra-peptide fragments was observed in the transgenic mice.

Herbert H Hill, Jr, PhD, a professor of Chemistry and senior author of the study, said, “The feces was not exactly the same as the tissue samples, but it had a lot of similarities to the tissue. We found the lipids and fatty acids were changing, and there were also changes in the amino acids. The exciting part is being able to see differences in the stool. This could lead to a noninvasive, more comprehensive early-warning detection method for colorectal cancer.” The study was published on October 4, 2016, in the Journal of Proteome Research.

Related Links:
Washington State University
Waters
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.